In clinical studies, Carlumab (anti-CCL2 monoclonal antibody) was proven to effectively resist the metastasis of prostate cancer by inhibiting the CCL2-CCR2 signaling pathway (NCT00992186) (Table 1). The gene discussed is CCL2; the disease is prostate carcinoma.